Hyperinsulinism Clinical Trial
Official title:
Pasireotide for Prevention of Hypoglycemia in Patients With Hyperinsulinemic Hypoglycemia
NCT number | NCT03053284 |
Other study ID # | 2016-7044 |
Secondary ID | |
Status | Withdrawn |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | April 2017 |
Est. completion date | April 2018 |
Verified date | May 2021 |
Source | Montefiore Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a small controlled pilot study to assess the effect of subcutaneous pasireotide on preventing hypoglycemia due to hyperinsulinism, including congenital hyperinsulinism and insulinoma.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | April 2018 |
Est. primary completion date | January 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion criteria: 1. Male or female patients aged 18 to 70 years old 2. Patients with hyperinsulinemic hypoglycemia due to either congenital hyperinsulinemic hypoglycemia or insulinoma, as determined by an endocrinologist 3. If no prior diagnosis of either insulinoma or congenital hyperinsulinemic hypoglycemia by an endocrinologist, the participant must meet the following criteria: - A history of symptoms of hypoglycemia, (with or without a blood glucose <50mg/dL at time of symptoms) - Improvement of symptoms with ingestion of carbohydrates - At least one documented blood glucose <50mg/dL with concomitant insulin >3 mmol/L and c-peptide >0.2nmol/L, with a negative sulfonylurea screen - At least 1 episode of glucose <50mg/dL in the last year 4. Written informed consent obtained prior to treatment to be consistent with local regulatory requirements 5. No evidence of significant liver disease: - Serum total bilirubin < 2 x ULN - INR < 1.3 unless on anticoagulation - ALT and AST < 2 x ULN - Alkaline phosphatase < 2.5 x ULN 6. Patients receiving anti-hypoglycemic treatment are eligible 7. Patients who are treatment naïve, or those who were previously, but not currently, treated with anti-hypoglycemic therapy are also eligible 8. Patients with insulinoma who are operative candidates are eligible if surgery is not emergently needed, and study participation would not delay the timing of a surgical intervention Exclusion criteria: 1. Age <18, age >70 (for both insulinoma and congenital hyperinsulinism) 2. Known hypersensitivity to somatostatin or analogues 3. Diabetic patients with poor glycemic control as evidenced by HbA1c >8% 4. Patients who are hypothyroid and not on adequate replacement therapy 5. Patients with symptomatic cholelithiasis and acute or chronic pancreatitis 6. QTcF at screening > 450 msec in males and QTcF > 460 msec in females 7. Hypokalaemia, hypomagnesaemia, family history of long QT syndrome or concomitant medications with known risk of Torsades de pointes (TdP) 8. Patients who have congestive heart failure (NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, clinically significant bradycardia, advanced heart block, history of acute MI less than one year prior to study entry or clinically significant impairment in cardiovascular function 9. Severe non-malignant medical illness that may be jeopardized by treatment with a single dose of pasireotide 10. History of another primary malignancy, with the exception of locally excised non-melanoma skin cancer and carcinoma in situ of uterine cervix unless there is no evidence of disease in the last year 11. Patients with serum creatinine >2.0 X ULN 12. Patients with WBC <3 X 109/L; Hb 90% < LLN; PLT <100 X 109/L 13. Patients with the presence of active or suspected acute or chronic uncontrolled infection 14. Patients who have undergone major surgery/surgical therapy for any cause within 4 weeks prior screening 15. History of unexplained syncope or family history of idiopathic sudden death 16. Sexually active males unless they use a condom during intercourse while taking drug and for 3 months following last dose of pasireotide and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid. 17. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test 18. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and 30 days following last dose of pasireotide. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Montefiore Medical Center | Novartis Pharmaceuticals |
Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab. 2009 Jan;94(1):115-22. doi: 10.1210/jc.2008-1008. Epub 2008 Oct 28. — View Citation
Braun M. The somatostatin receptor in human pancreatic ß-cells. Vitam Horm. 2014;95:165-93. doi: 10.1016/B978-0-12-800174-5.00007-7. Review. — View Citation
de Heide LJ, Laskewitz AJ, Apers JA. Treatment of severe postRYGB hyperinsulinemic hypoglycemia with pasireotide: a comparison with octreotide on insulin, glucagon, and GLP-1. Surg Obes Relat Dis. 2014 May-Jun;10(3):e31-3. doi: 10.1016/j.soard.2013.11.006. Epub 2013 Dec 4. — View Citation
Eigler T, Ben-Shlomo A. Somatostatin system: molecular mechanisms regulating anterior pituitary hormones. J Mol Endocrinol. 2014 Aug;53(1):R1-19. doi: 10.1530/JME-14-0034. Epub 2014 Apr 29. Review. — View Citation
Hansen L, Hartmann B, Mineo H, Holst JJ. Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum. Regul Pept. 2004 Apr 15;118(1-2):11-8. — View Citation
Quinn TJ, Yuan Z, Adem A, Geha R, Vrikshajanani C, Koba W, Fine E, Hughes DT, Schmid HA, Libutti SK. Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model. Surgery. 2012 Dec;152(6):1068-77. doi: 10.1016/j.surg.2012.08.021. Epub 2012 Oct 24. — View Citation
Schmid HA, Brueggen J. Effects of somatostatin analogs on glucose homeostasis in rats. J Endocrinol. 2012 Jan;212(1):49-60. doi: 10.1530/JOE-11-0224. Epub 2011 Oct 10. — View Citation
Tirosh A, Stemmer SM, Solomonov E, Elnekave E, Saeger W, Ravkin Y, Nir K, Talmor Y, Shimon I. Pasireotide for malignant insulinoma. Hormones (Athens). 2016 Apr;15(2):271-276. doi: 10.14310/horm.2002.1639. — View Citation
Yorifuji T. Congenital hyperinsulinism: current status and future perspectives. Ann Pediatr Endocrinol Metab. 2014 Jun;19(2):57-68. doi: 10.6065/apem.2014.19.2.57. Epub 2014 Jun 30. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Collection of safety and adverse event data | 7 hours | |
Primary | Hypoglycemia | Occurence, frequency and severity of hypoglycemia (serum glucose < 55 mg/dL) | 7 hours | |
Secondary | Serum glucose regulators | Insulin, GLP-1, glucagon and cortisol levels | 7 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00073775 -
Epidemiology of Stress and the Metabolic Syndrome
|
N/A | |
Completed |
NCT00074451 -
Genomewide Search for Loci Underlying Metabolic Syndrome
|
||
Completed |
NCT00005380 -
Insulin, Androgen, and Risk in African-American Women
|
N/A | |
Completed |
NCT00005709 -
Lipoprotein Metabolism in Hypertensive African-Americans
|
N/A | |
Recruiting |
NCT05088798 -
Utility of 18FDOPA PET/MRI for Focal Hyperinsulinism
|
Phase 2 | |
Not yet recruiting |
NCT05950282 -
Fasting Insulin and HOMA-IR by Age, Sex, Race/Ethnicity, BMI, and PCOS Diagnosis
|
||
Completed |
NCT02248272 -
Effect of Meal Frequency on Glycemic Control of People at High Risk or Diagnosed With Diabetes
|
N/A | |
Completed |
NCT00937079 -
Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients
|
Phase 1 | |
Completed |
NCT00151684 -
Diazoxide-Mediated Insulin Suppression in Hyperinsulinemic Obese Men
|
Phase 2 | |
Completed |
NCT00004825 -
Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism
|
N/A | |
Completed |
NCT00005530 -
Diet, Insulin Resistance, and Cardiovascular Risk
|
N/A | |
Recruiting |
NCT05662189 -
Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus
|
N/A | |
Recruiting |
NCT04744896 -
Effects Of Combined Cryolipolysis And High Intensity Interval Training On Insulin Resistance And Body Composition In Polycystic Ovarian Patients
|
N/A | |
Completed |
NCT05329337 -
Link Between the Peripheral Mononuclear Cells' Capacity to Induce Insulin Resistance and Hyperinsulinemia
|
N/A | |
Not yet recruiting |
NCT05989347 -
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy
|
Phase 1 | |
Recruiting |
NCT05543083 -
Cognitive-Behavioral Therapy and Exercise Training in Adolescents At-Risk for Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05774613 -
Effect of Hibiscus Sabdariffa Beverage
|
N/A | |
Recruiting |
NCT06363929 -
Continuous Glucose Monitoring in Neonatal Hyperinsulinism
|
||
Completed |
NCT03358745 -
Impact of Meal Order on Postprandial Cardiometabolic Risk Markers
|
N/A | |
Not yet recruiting |
NCT05764200 -
Acute Microbial Switch
|
N/A |